Men's Health: The Market for Current and Emerging Drug Therapies, 2nd Edition

Table of Contents

Chapter One: Executive Summary

• Introduction
• Scope and Methodology
• Size and Growth of the Market
• Issues and Trends Affecting Market
• Leading Competitors

Chapter Two: Introduction

• History and Growth of the Men's Health Industry
• Male Anatomy
• Male Reproductive Physiology
• Male Demographics and Statistics

chapter Three: Men's Cancer

• Overview
  • Description of Cancers Affecting Men
  • Prostate Cancer
  • Testicular Cancer
  • Prevalence and Incidence
• Description of Products
  • Hormone Therapies
  • LHRH Analogs
  • Antiandrogens
  • Intermittent Hormone Therapy
  • Adjuvant Hormone Therapy
  • Chemotherapy Agents
  • Brachytherapy
• Research and Development
• Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
  • Competitive analysis

chapter Four: Male Sexual Dysfunction

• Overview
  • Description of Sexual Disorders Affecting Men
  • Erectile Dysfunction
  • Ejaculation Disorders
  • Prevalence and Incidence
• Description of Products
  • Phosphodiesterase Type V Inhibitors (PDE-5 Inhibitors)
  • Others
• Research and Development
• Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
• Competitive Analysis

chapter Five: Sexually Transmitted Diseases

• Overview
  • Description of Sexually Transmitted Diseases Affecting Men
  • Chlamydia
  • Genital Herpes
  • Genital Warts
  • Gonorrhea
  • HIV/AIDS
  • Syphilis
  • Prevalence and Incidence
• Description of Products
  • Antibiotics
  • Antiviral Therapies
  • Others
• Research and Development
  • Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
  • Competitive Analysis

chapter Six: Men's Urinary Conditions

• Overview
  • Description of Urinary Conditions Affecting Men
  • Benign Prostate Hypertrophy (BPH)
  • Prostatitis
  • Urinary Incontinence
  • Prevalence and Incidence
• Description of Products
  • Alpha Blockers
  • 5-Alpha Reductase Inhibitors
  • Anticholinergics
  • Antispasmodics and Others
• Research and Development
• Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
  • Competitive Analysis

chapter Seven: Male Menopause or Andropause

• Overview
  • Description of Male Menopause
  • Prevalence and Incidence
• Description of Products
• Research and Development
• Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
• Competitive Analysis

Chapter Eight: Issues and Trends Affecting the Men's Health Market

• Introduction
• Education and Awareness of Men's Health
• Office of Men's Health
• Changing Life Expectancy
• Diabetes and Sleep
• Early Detection and Screening of Prostate Cancer
• Blacks and Prostate Cancer
• Erectile Dysfunction and CAD
• Cosmetic Surgery
• Bladder Cancer Detection
• Lifestyle Changes and Prostate Cancer
• Effects of Testosterone Dosage on Behavior of Older Men
• Testosterone Replacement Therapy Decreases Fat and Increases Muscle
• Men of All Ages Respond to Building Muscle Mass with Testosterone Doses

Chapter Nine: Market Summary

• Overview
• Market Size and Forecast
  • World Market
  • Markets by Segments
• Competitor Analysis
• Market Outlook

chapter Ten: Corporate Profiles

• Introduction
• Current Market Leaders Profiles
• Abbott Laboratories
• Astellas Pharma Inc.
• ALZA Corporation
• AstraZeneca plc
• Bayer Corporation
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Eli Lilly & Company
• GlaxoSmithKline plc
• Merck & Company, Inc.
• Pfizer, Inc.
• Roche Group
• Sanofi-Aventis
• Takeda Chemical Industries, Ltd.
• TAP Pharmaceutical Products, Inc.
• Unimed Pharmaceuticals, Inc.
• VIVUS, Inc.
• Watson Pharmaceuticals, Inc.

Appendix: Company Directory

List of Exhibits

Chapter One: Executive Summary

• Table 1-1: The World Market for Men's Health Prescription Drugs 2003-2010
• Figure 1-1: Trending in the World Market Men's Health, 2003-2010

Chapter Two: Introduction

• Table 2-1: World Male Population by Selected Geographical Region 2005-2050
• Table 2-2: Life Expectancy at Birth by Selected Countries, 2000
• Table 2-3: United States Life Expectancy at Birth, 1990-2000, and Projections, 2005-2010
• Table 2-4: Estimated Male Prevalence of Selected Risk Behavior by Geographical Region, 2005
• Figure 2-1: Estimated Male Prevalence of Selected Risk Behavior by Geographical Region, 2005

chapter Three: Men's Cancer

• Table 3-1: Men's Cancer: Estimated World Incidence and Prevalence
• Figure 3-1: Men's Cancer: World Incidence
• Table 3-2: Research and Development in Men's Cancer Therapies (Product, Developer, Phase, Drug Class, Projected Approval Date)
• Table 3-3: The World Market Men's Health: Men's Cancer Therapies by Product Type (Hormone Therapy, Chemotherapy) 2003-2010
• Figure 3-2: Trending in the World Market for Men's Cancer Therapies 2003-2010
• Table 3-4: The U.S. Market Men's Cancer Therapies 2003-2010
• Figure 3-3: Trending in the U.S. Market for Men's Cancer Therapies 2003-2010
• Table 3-5: The International (Non-U.S.) Market for Men's Cancer Therapies 2003-2010
• Figure 3-4: Trending in the International (Non-U.S.) Market for Men's Cancer Therapies, 2003-2010
• Table 3-6: Leading Suppliers' Revenues and Market Shares of the World Market for Men's Cancer Therapies Estimated 2005 and Projected 2010
• Figure 3-5: Leading Suppliers Market Share of the World Market for Men's Cancer Therapies, 2005 and 2010

chapter Four: Male Sexual Dysfunction

• Table 4-1: Estimated World and U.S. Incidence and Prevalence of Male Sexual Dysfunction by Type (Erectile Dysfunction, Premature Ejaculation)
• Figure 4-1: World Prevalence of Men's Sexual Dysfunction
• Table 4-2: PDE-5 Inhibitor Comparison Chart
• Table 4-3: Research and Development in Men's Sexual Dysfunction (Product, Developer, Phase, Drug Class, Projected Approval Date)
• Table 4-4: The World Market Men's Sexual Dysfunction Therapies by Product Type (PDE-5 Inhibitors and Others) 2003-2010
• Figure 4-2: Trending in the World Market for Men's Sexual Dysfunction Therapies 2003-2010
• Table 4-5: The U.S. Market for Men's Sexual Dysfunction Therapies 2003-2010
• Figure 4-3: Trending in the U.S. Market for Men's Sexual Dysfunction Therapies 2003-2010
• Table 4-6: The International (Non-U.S.) Market for Men's Sexual Dysfunction Therapies 2003-2010
• Figure 4-4: Trending in the International (Non-U.S.) Market for Men's Sexual Dysfunction Therapies 2003-2010
• Table 4-7: Leading Suppliers' Revenues and Market Shares of the World Market for Men's Sexual Dysfunction Therapies Estimated 2005 and Projected 2010
• Figure 4-5: Leading Suppliers' Market Shares of the World Market for Men's Sexual Dysfunction Therapies, 2005 and 2010

chapter Five: Sexually Transmitted Diseases

• Table 5-1: Men's Sexually Transmitted Diseases: Estimated World Incidence
• and Prevalence for Men (in thousands)
• Figure 5-1: Men's Sexually Transmitted Diseases: World Incidence
• Table 5-2: Research and Development in Sexually Transmitted Disease Therapeutics (Product, Developer, Phase, Drug Class, Indication, Projected Approval Date for Phase III)
• Table 5-3: The World Market Men's Sexually Transmitted Disease Therapies by Product Type (Antibiotics, Antivirals, Others) 2003-2010
• Figure 5-2: Trending in the World Market for Men's Sexually Transmitted Disease Therapies 2003-2010
• Table 5-4: The U.S. Market Men's Sexually Transmitted Disease Therapies 2003-2010
• Figure 5-3: Trending in the U.S. Market for Men's Sexually Transmitted Disease Therapies, 2003-2010
• Table 5-5: The International (Non-U.S.) Market for Men's Sexually Transmitted Disease Therapies 2003-2010
• Figure 5-4: Trending in the International (Non-U.S.) Market for Men's Sexually Transmitted Disease Therapies 2003-2010
• Table 5-6: Leading Suppliers' Revenues and Market Shares of the World Market for Men's Sexually Transmitted Disease Therapies Estimated 2005 and Projected 2010
• Figure 5-5: Leading Suppliers' Market Shares of the World Market for Men's Sexually Transmitted Disease Therapies 2005 and 2010

chapter Six: Men's Urinary Conditions

• Table 6-1: Estimated World Incidence and Prevalence for Men's Urinary
• Conditions (BPH and Urinary Incontinence; in thousands)
• Figure 6-1: Men's Urinary Conditions: World Prevalence
• Table 6-2: Research and Development in Urinary Condition Therapeutics (Product, Developer, Phase, Drug Class, Indication, Projected Approval Date for Phase III)
• Table 6-3: The World Market Men's Urinary Condition Therapies by Product Type (Hormone Therapy, Chemotherapy) 2003-2010
• Figure 6-2: Trending in the World Market for Men's Urinary Condition Therapies 2003-2010
• Table 6-4: The U.S. Market for Men's Urinary Condition Therapies 2003-2010
• Figure 6-3: Trending in the U.S. Market for Men's Urinary Condition Therapies 2003-2010
• Table 6-5: The International (Non-U.S.) Market for Men's Urinary Condition Therapies 2003-2010
• Figure 6-4: Trending in the International (Non-U.S.) Market for Men's Urinary Condition Therapies 2003-2010
• Table 6-6: Leading Suppliers' Revenues and Market Shares of the World Market for Men's Urinary Condition Therapies Estimated 2005 and Projected 2010
• Figure 6-5: Leading Suppliers Market Shares of the World Men's Urinary Condition Therapies Market 2005 and 2010

chapter Seven: Male Menopause or Andropause

• Table 7-1: Estimated World Incidence and Prevalence of Andropause (in thousands)
• Figure 7-1: World Prevalence of Andropause (Low and High Range)
• Table 7-2: Research and Development in Sexually Transmitted Disease Therapeutics (Product, Developer, Phase, Drug Class, Projected Approval Date)
• Table 7-3: The World Market for Andropause Therapies 2003-2010
• Figure 7-2: Trending in the World Market for Andropause Therapies 2003-2010 Table 7-4: The U.S. Market for Andropause Therapies 2003-2010
• Figure 7-3: Trending in the U.S. Market for Andropause Therapies 2003-2010
• Table 7-5: The International (Non-U.S.) Market for Andropause Therapies 2003-2010
• Figure 7-4: Trending in the International (Non-U.S.) Market for Andropause Therapies 2003-2010
• Table 7-6: Leading Suppliers' Revenues and Market Shares of the World Market for Andropause Therapies Estimated 2005 and Projected 2010

Chapter Eight: Issues and Trends Affecting the Men's Health Market

• Table 8-1: Relative Risk Related to Family History of Prostate Cancer

Chapter Nine: Market Summary

• Table 9-1: The World Market for Men's Health Prescription Drugs 2003-2010
• Table 9-2: The World Market for Men's Health Prescription Drugs by Segment (Men's Cancer, Sexual Function, Sexually Transmitted Diseases, Urinary Conditions, Andropause) 2003-2010
• Figure 9-1: Trending in the World Market for Men's Health Therapeutics 2003-2010
• Figure 9-2: Distribution of Revenues in the World Market for Men's Health Therapeutics by Product Type 2005
• Table 9-4: Leading Suppliers and Significant Segments of Participation 2005